Photo of Paolo Tarantino taken from Twitter
Feb 8, 2024, 05:08
Paolo Tarantino: From no anti-HER2 drugs to a plethora of emerging options
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on Twitter/X:
“From no anti-HER2 drugs to a plethora of emerging options: promising days for targeting HER2+ colorectal cancer with TKIs, mAbs and ADCs. Check out our review on HER2+ CRC, just out in the first issue of ESMO-GI!”
View additional information.
Source: Paolo Tarantino/X